CIK 0001178670
- Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770602661
- Phone
- +1 617-551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-25 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −26 | $226.82 | $6K | 15,286 |
| 2024-06-25 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −96 | $228.30 | $22K | 15,190 |
| 2024-06-25 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −198 | $229.06 | $45K | 14,992 |
| 2024-06-25 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −227 | $229.93 | $52K | 14,765 |
| 2024-06-25 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −74 | $231.59 | $17K | 14,691 |
| 2024-06-25 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −161 | $232.54 | $37K | 14,530 |
| 2024-06-25 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −86 | $233.53 | $20K | 14,444 |
| 2024-06-25 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −138 | $234.66 | $32K | 14,306 |
| 2024-06-25 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −125 | $235.19 | $29K | 14,181 |
| 2024-06-24 | PYOTT DAVID E I Director | Exercise or conversion 10b5-1 | +17,560 | $88.95 | $1.6M | 17,696 |
| 2024-06-24 | PYOTT DAVID E I Director | Exercise or conversion 10b5-1 | +7,420 | $70.20 | $521K | 25,116 |
| 2024-06-24 | PYOTT DAVID E I Director | Exercise or conversion 10b5-1 | +7,470 | $71.99 | $538K | 32,586 |
| 2024-06-24 | PYOTT DAVID E I Director | Sale 10b5-1 | −17,560 | $220.00 | $3.9M | 15,026 |
| 2024-06-24 | PYOTT DAVID E I Director | Sale 10b5-1 | −7,420 | $221.00 | $1.6M | 7,606 |
| 2024-06-24 | PYOTT DAVID E I Director | Sale 10b5-1 | −7,470 | $222.00 | $1.7M | 136 |
| 2024-06-24 | PYOTT DAVID E I Director | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −7,420 | 3,830 | ||
| 2024-06-24 | PYOTT DAVID E I Director | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −7,470 | 3,780 | ||
| 2024-06-24 | PYOTT DAVID E I Director | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −17,560 | 7,440 | ||
| 2024-06-24 | Garg Pushkal CMO & EVP Dev & Med Affairs | Grant or award | +4,295 | 17,712 | ||
| 2024-06-24 | Greenstreet Yvonne Chief Executive Officer | Grant or award | +16,953 | 88,835 |
Page 46 of 80 · 1,590 trades